alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing of the Annual Report on Form 10-K for the year ended December 31, 2009 (the Report) by First California Financial Group, Inc. (Registrant), each of the undersigned hereby certifies
that:



| | 1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
| | -- | ---------------------------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Registrant.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------

Date: March 5, 2010



/s/ C. G. KumC. G. Kum President and Chief Executive Officer/s/ Romolo SantarosaRomolo Santarosa Executive Vice President and Chief Financial Officer
II 

118TH CONGRESS 

1ST SESSION S. 600 

To amend the Controlled Substances Act to list fentanyl-related substances 

as schedule I controlled substances. 

IN THE SENATE OF THE UNITED STATES 

MARCH 1, 2023 

Mr. JOHNSON (for himself, Mr. BRAUN, Mr. COTTON, and Mr. MCCONNELL) 

introduced the following bill; which was read twice and referred to the 

Committee on the Judiciary 

A BILL 

To amend the Controlled Substances Act to list fentanylrelated substances as schedule I controlled substances. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stopping Overdoses 

5 of Fentanyl Analogues Act’’. 

6 SEC. 2. FENTANYL-RELATED SUBSTANCES. 

7 (a) IN GENERAL.—Schedule I of section 202(c) of 

8 the Controlled Substances Act (21 U.S.C. 812(c)) is 

9 amended by adding at the end the following: 


kjohnson on DSK79L0C42PROD with BILLS
2 

•S 600 IS

1 ‘‘(e)(1) Unless specifically exempted or unless listed 

2 in another schedule, any material, compound, mixture, or 

3 preparation which contains any quantity of fentanyl-re4 lated substances, including their isomers, esters, ethers, 

5 salts, and salts of isomers, esters, and ethers, whenever 

6 the existence of such isomers, esters, ethers, and salts is 

7 possible within the specific chemical designation. 

8 ‘‘(2) In paragraph (1), the term ‘fentanyl-related sub9 stances’ includes any substance that is structurally related 

10 to fentanyl by 1 or more of the following modifications: 

11 ‘‘(A) By replacement of the phenyl portion of 

12 the phenethyl group by any monocycle, whether or 

13 not further substituted in or on the monocycle. 

14 ‘‘(B) By substitution in or on the phenethyl 

15 group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, 

16 haloalkyl, amino, or nitro groups. 

17 ‘‘(C) By substitution in or on the piperidine 

18 ring with alkyl, alkenyl, alkoxyl, ester, ether, 

19 hydroxyl, halo, haloalkyl, amino, or nitro groups. 

20 ‘‘(D) By replacement of the aniline ring with 

21 any aromatic monocycle whether or not further sub22 stituted in or on the aromatic monocycle. 

23 ‘‘(E) By replacement of the N-propionyl group 

24 by another acyl group.’’. 


kjohnson on DSK79L0C42PROD with BILLS
3 

•S 600 IS

1 (b) EFFECTIVE DATE.—This Act shall take effect 1 

2 day after the date of enactment of this Act. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
ASSIGNMENT OF LICENSE AGREEMENT


     FOR  VALUE  RECEIVED,  Michael  Kirsh  ("Assignor"),  for good and valuable
consideration,  does  hereby  sell, assign, and transfer to Supplife.com Inc., a
Washington  corporation  ("Assignee"),  all of the rights, title and interest of
Assignor  and  delegates  to  Assignee  all of the duties of Assignor under that
certain  License  Agreement  dated November 14, 2000 by and between Assignor and
Vitamineralherb.com Corp., a Nevada Corporation, a true copy of which is annexed
hereto  and  made  a  part  hereof.

     Assignor  represents  that  the  annexed  contract  is  a valid and binding
agreement in all respects, is assignable and the duties hereunder delegable, and
that  this  assignment  and  delegation  is  a  valid exercise of the Assignor's
rights.

     Assignee hereby assumes and agrees to perform all of Assignor's obligations
under the annexed  contract.  Assignee shall defend, indemnify and hold harmless
Assignor,  from  and against any claim, liability and expense which Assignee may
incur (including without limitation attorneys fees and litigation expenses) that
arises  out  of Assignee's performance of, or failure to perform, such contract.


Dated this 14th day of November, 2000.


ASSIGNOR:                                          ASSIGNEE:

                                                   Supplife.com  Inc.


   /s/  Michael  Kirsh                                /s/  Marie  Gruson
-----------------------------                      -----------------------------
Michael  Kirsh                                     Marie  Gruson,  President


ASSIGNMENT OF LICENSE                                               PAGE 1  OF 1
<PAGE>
#### § 1800.10 Fees.

If an individual requests copies of his or her record, he or she shall be charged ten cents per page, excluding the cost of any search for review of the record, in advance of receipt of the pages.
#### § 1643.1 Purpose.

This part is intended to ensure that recipients do not use any LSC funds for any assisted suicide, euthanasia or mercy killing activities prohibited by this part.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                        488,451
<TOTAL-REVENUES>                               488,451
<CGS>                                          359,068
<TOTAL-COSTS>                                  374,035
<OTHER-EXPENSES>                               107,247
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               8,328
<INCOME-PRETAX>                                 (1,436)
<INCOME-TAX>                                      (570)
<INCOME-CONTINUING>                               (866)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  2,198    
<CHANGES>                                            0
<NET-INCOME>                                    (3,064)
<EPS-PRIMARY>                                    (0.75)
<EPS-DILUTED>                                    (0.59)
        

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### United States Institute of Peace

# Date/Time:

Tuesday, November 28, 2006, 9 a.m.-3 p.m.

# Location:

1200 17th Street, NW., Suite 200, Washington, DC 20036-3011.

# Status:

Open Session—Portions may be closed pursuant to Subsection (c) of Section 552(b) of Title 5, United States Code, as provided in subsection 1706(h)(3) of the United States Institute of Peace Act, Public Law 98-525.

# Agenda:

November 28, 2006 Board Meeting; Approval of Minutes of the One Hundred Twenty-Fourth Meeting (September 28, 2006) of the Board of Directors; Chairman's Report; President's Report; Budget Update; Iraq Study Group Update; Other General Issues.

# Contact:

Tessie F. Higgs, Executive Office, Telephone: (202) 429-3836.

Dated: November 20, 2006.

Patricia P. Thomson,

Executive Vice President, United States Institute of Peace.

[FR Doc. 06-9415  Filed 11-22-06; 10:33 am]

BILLING CODE 6820-AR-M
#### §§ 2490.161-2490.169 [Reserved]
EXHIBIT 31.1

             CERTIFICATION PURSUANT TO RULE 13A-14(D)/15D-14(D)
                  UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Anthony N. Renzi, certify that:
1. I have  reviewed  this  report  on Form  10-K and all  reports  on Form  10-D
   required to be filed in respect of the period  covered by this report on Form
   10-K of RALI Series 2006-QS11 Trust (the "Exchange Act periodic reports");
2. Based on my knowledge,  the Exchange Act periodic reports,  taken as a whole,
   do not contain  any untrue  statement  of a material  fact or omit to state a
   material  fact  necessary  to make  the  statements  made,  in  light  of the
   circumstances  under which such  statements  were made, not  misleading  with
   respect to the period covered by this report;
3. Based  on  my  knowledge,  all  of  the  distribution,  servicing  and  other
   information required to be provided under Form 10-D for the period covered by
   this report is included in the Exchange Act periodic reports;
4. I am responsible for reviewing the activities  performed by the servicers and
   based on my knowledge and the compliance  reviews  conducted in preparing the
   servicer  compliance  statements  required in this report  under Item 1123 of
   Regulation AB, and except as disclosed in the Exchange Act periodic  reports,
   the servicers have fulfilled their obligations under the servicing agreements
   in all material respects; and
5. All of the reports on assessment of compliance  with  servicing  criteria for
   asset-backed  securities and their related  attestation reports on assessment
   of compliance with servicing criteria for asset-backed securities required to
   be included in this report in accordance  with Item 1122 of Regulation AB and
   Exchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to this
   report,  except as otherwise disclosed in this report. Any material instances
   of noncompliance described in such reports have been disclosed in this report
   on Form 10-K.

   In giving the  certifications  above, I have reasonably relied on information
   provided  to  me  by  the  following   unaffiliated  parties:  HSBC  Mortgage
   Corporation (USA),  National City Mortgage Co., Wachovia Mortgage Corporation
   and Deutsche Bank Trust Company Americas.

Date:  March 26, 2007

By:   /s/ Anthony N. Renzi
Name:  Anthony N. Renzi
Title:    Managing Director
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the Public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Cystic Fibrosis Research and Translation Core Centers (P30).                    

*Date:*                         January 10, 2007.                    

*Time:*                         8 a.m. to 4 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Courtyard Marriott, 2899 Jefferson Davis Highway, Arlington, VA 22202.                    

*Contact Person:*                         Dan E. Matsumoto, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, National Institutes of Health;  Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892-5452. (301) 594-8894.                         *matsumotod@extra.niddk.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 21, 2006.

David Clary,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 06-9456 Filed 11-28-06; 8:45 am]

BILLING CODE 4140-01-M
Exhibit 35.1





Annual Statement of Compliance





VIA: EMAIL





MS Structured Asset Corp.


1585 Broadway


New York, New York 10036





Re:
TRUST AGREEMENT, between MS Structured Asset Corp. (the “Depositor”) and LaSalle Bank National Association (the “Trustee”), made as of the date August 2, 2006 relating to SATURNS Trust No. 2006-2.





I, Thomas M. O’Connor, a Senior Vice President of Bank of America, National Association as successor by merger to LaSalle Bank National Association, as Trustee hereby certify that:





1.  A review of the activities of the Trustee during the preceding calendar year and of the performance of the Trustee under the Agreement has been made under my supervision; and





2.  To the best of my knowledge, based on such review, the Trustee has fulfilled all its obligations under the Agreement in all material respects throughout such year or a portion thereof.














Date:  2/17/2011





Bank of America, National Association as successor by merger to LaSalle Bank National Association, as Trustee








/s/Thomas M. O'Connor_____________________________


Thomas M. O’Connor


Senior Vice President
Exhibit 32.2



CHIEF FINANCIAL OFFICERS

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report
of First Place Financial Corp. (First Place) on Form 10-Q for the period ended March 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, David L. Mead, Chief Financial Officer of
First Place, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
| | --- | ------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of First Place.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|             |  |                        
|------------ |  | -----------------------
|May 13, 2004 |  | /s/ David L. Mead      
|             |  | David L. Mead          
|             |  | Chief Financial Officer
Exhibit 32.1




CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of Implant Sciences Corporation, a Massachusetts corporation (the “Company”) on Form 10-Q for the period ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Glenn D. Bolduc, President, Chief Executive Officer and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:




(1)       The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)       The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.




/s/Glenn D. BolducGlenn D. BolducPresident, Chief Executive Officer and Chief Financial OfficerDate: May 19, 2010







This certification accompanies each report of the Company on Form 10-Q and Form 10-K pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by we for purposes of §18 of the Securities Exchange Act of 1934, as amended.




A signed original of this written statement required by §906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or our staff upon request.
---

EXHIBIT 23.1

The Board of Directors 
China Biologic Products, Inc.:

We consent to the incorporation by reference in the
registration statement (No. 333-171069) on Form S-3 of China Biologic Products,
Inc. (the "Company") of our reports dated March 31, 2011, with respect to the
consolidated balance sheet of the Company and subsidiaries as of December 31,
2010, and the related consolidated statements of income, stockholders equity
and comprehensive income, and cash flows for the year then ended, and the
effectiveness of internal control over financial reporting as of December 31,
2010, which reports appear in the December 31, 2010 annual report on Form 10-K
of the Company.

Our report dated March 31, 2011, with respect to the
consolidated balance sheet of the Company and subsidiaries as of December 31,
2010, and the related consolidated statements of income, stockholders equity
and comprehensive income, and cash flows for the year then ended, contains an
explanatory paragraph states that the Companys subsidiary, Guizhou Taibang
Biological Products Co., Ltd. ("Guizhou Taibang") is a defendant in a lawsuit
brought by certain potential investors with respect to Guizhou Taibangs failure
to register their capital contributions in Guizhou Taibang with the local
Administration for Industry and Commerce.

Our report dated March 31, 2011, on the effectiveness of
internal control over financial reporting as of December 31, 2010, expresses our
opinion that China Biologic Products, Inc. did not maintain effective internal
control over financial reporting as of December 31, 2010 because of the effect
of two material weaknesses on the achievement of the objectives of the control
criteria and contains an explanatory paragraph that states that material
weaknesses related to review controls on the determination of fair values of
derivative instruments and the recognition of deferred tax liabilities upon
business combination have been identified and included in managements
assessment.

Our report dated March 31, 2011, on the effectiveness of
internal control over financial reporting as of December 31, 2001, contains an
emphasis of matter paragraph that states that we do not express an opinion or
any other form of assurance on managements statements referring to corrective
actions taken after December 31, 2010, relative to the aforementioned material
weaknesses in internal control over financial reporting.

/s/ KPMG 
Hong Kong, China 
March 31, 2011

---
EXHIBIT 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

I, Bobba Venkatadri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Trans-India Acquisition Corporation for the year ended December 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934 and that information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Trans-India Acquisition Corporation.



|                      |  |     |  |                        
|--------------------- |  | --- |  | -----------------------
|Dated: March 30, 2007 |  | By: |  | /s/ BOBBA VENKATADRI   
|                      |  |     |  | Bobba Venkatadri       
|                      |  |     |  | Chief Executive Officer

I, Craig Colmar, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Trans-India Acquisition Corporation for the year ended December 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934 and that information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Trans-India Acquisition Corporation.



|                      |  |     |  |                            
|--------------------- |  | --- |  | ---------------------------
|Dated: March 30, 2007 |  | By: |  | /s/ CRAIG COLMAR           
|                      |  |     |  | Craig Colmar               
|                      |  |     |  | Principal Financial Officer
Court of Appeals of the State of Georgia

Clerk's Office, Atlanta, July 12, 2018.

I certify that the above is a true extract from the minutes 

of the Court of Appeals of Georgia.

Witness my signature and the seal of said court hereto 

affixed the day and year last above written.

, Clerk.

Court of Appeals 

of the State of Georgia

ATLANTA, July 12, 2018

The Court of Appeals hereby passes the following order

A18D0516. MARK ANDREW HILDERBRAND v. THE STATE.

Upon consideration of the Application for Discretionary Appeal, it is ordered that it be 

hereby DENIED.

LC NUMBERS:

09CR00169